Identification of the severe acute respiratory syndrome coronavirus 2 in humans toward the end of 2019 triggered a rapid. intensive effort to develop a vaccine. Among the first three COVID-19 vaccines granted emergency use authorization by the U. S. https://www.campicon.com/